My hope for the 113 trial is that it will be an extremely robust Phase I, and that the delay has been in developing the trial with FDA input so that it yields sufficient data to move to a pivotal Ph 2.
I really can't see HB rolling out some kind of 17-patient safety trial after all this time -- that would be a bit of a disaster, no?